AstraZeneca Links With Accent To Target RNA-Modifying Proteins

Pact Spans Discovery, Development And Commercialization

 
• By Sten Stovall

AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.

DNA_Strand
Deal gives $55m upfront to Accent, a specialist in RNA modification • Source: Shutterstock

More from Clinical Trials

More from R&D